News

The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still ...
After the FDA request, Cambridge, Massachusetts-based Sarepta said in a statement that it will continue to ship the therapy to ambulatory people but maintain a halt it implemented June 15 for ...